Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is a heterogeneous cancer in which sorafenib is the only approved systemic therapy. Histone deacetylases (HDAC) are commonly dysregulated in cancer and therefore represent promising targets for therapies, however their role in HCC pathogenesis is...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Lachenmayer, Anja, Toffanin, Sara, Cabellos, Laia, Alsinet, Clara, Hoshida, Yujin, Villanueva, Augusto, Minguez, Beatriz, Tsai, Hung-Wen, Ward, Stephen C., Thung, Swan, Friedman, Scott L., Llovet, Josep M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2012
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3355195/
https://ncbi.nlm.nih.gov/pubmed/22322234
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jhep.2012.01.009
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi